Search Results | Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Abstract 2179: Antitumor activity of JNJ-63576253 (TRC253), a small molecule antagonist of F877L mutant and wild-type androgen receptor

Tammy L. Bush, Georges Habineza Ndikuyeze, Gilles Bignan, Jonathan Branch, Janine Ondrus, Yifan Shi, Leopoldo Luistro, James Hastings, Joseph Erhardt, Ian Hickson, Shefali Patel, Peter Connolly, Zhuming Zhang, James Bischoff, Brent Rupnow, Marco Gottardis, Kathryn Packman

Cancer Res (2019) 79 (13_Supplement): 2179.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2179

Published: 01 July 2019

View article

Journal Articles

Abstract 359: A high-throughput PPI assay to quantify inhibition of androgen receptor variant 7 (AR-V7) binding to canonical AR full-length (AR-FL) binding partners

Jonathan Branch, Michael Quigley, Marco Gottardis, Ian Hickson

Cancer Res (2016) 76 (14_Supplement): 359.

DOI: https://doi.org/10.1158/1538-7445.AM2016-359

Published: 15 July 2016

View article

Journal Articles

Abstract 86: Live-cell profiling of inhibitors targeting the N/C interaction within the androgen receptor

Larisa Yurlova, Andrea Buchfellner, Jacqueline Gregor, Tina Romer, Ian Hickson

Cancer Res (2015) 75 (15_Supplement): 86.

DOI: https://doi.org/10.1158/1538-7445.AM2015-86

Published: 01 August 2015

View article

Journal Articles

Abstract 2023: Complex in vitro and in vivo prostate cancer models for the PREDECT consortium

Suzana Vidic, Norbert Esser, Ronald de Hoogt, Ingrid Verberne, Ira Kogan-Sakin, Yan Stein, Varda Rotter, Michael Barbier, Yolanda Chong, Sabine D. Breucker, Karine Smans, Malin Akerfelt, Matthias Nees, Peter King, Ian Hickson, Wytske van Weerden, Ralph Graeser

Cancer Res (2014) 74 (19_Supplement): 2023.

DOI: https://doi.org/10.1158/1538-7445.AM2014-2023

Published: 01 October 2014

View article

Journal Articles

Abstract 5386: Disrupting p53:Mdm2 and p53:Mdm4 - Comparative cell-based assays for drug screening

Larisa Yurlova, Christopher J. Brown, Maarten Derks, Farid John Ghadessy, Ian Hickson, David P. Lane, Eberhard Krausz, Kourosh Zolghadr

Cancer Res (2014) 74 (19_Supplement): 5386.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5386

Published: 01 October 2014

View article

Journal Articles

Abstract 4770: Dual activity of abiraterone: CYP17 mediated androgen ablation and direct AR inhibition.

Matthijs J. Moll, Robert J. van Soest, Jinpei Kumagai, Ralph Graeser, Ian Hickson, Guido W. Jenster, Wytske M. van Weerden

Cancer Res (2013) 73 (8_Supplement): 4770.

DOI: https://doi.org/10.1158/1538-7445.AM2013-4770

Published: 15 April 2013

View article

Journal Articles

Abstract LB-248: Investigation of tumor cell activity of Abiraterone using in vitro model systems of androgen (A)-responsive prostate cancer

Ann Marien, Maarten Derks, Marc Janssen, Ian Hickson

Cancer Res (2012) 72 (8_Supplement): LB-248.

DOI: https://doi.org/10.1158/1538-7445.AM2012-LB-248

Published: 15 April 2012

View article

Journal Articles

Abstract 2606: Rational combinations with the HDAC inhibitor, JNJ-26481585, in prostate cancer

Ian Hickson, Ann Marien, Marc Janssen, Maarten Derks, Peter King, Tinne Verhulst, Boudewijn Janssens, Hinrich Goehlmann, Ilse Van Den Wyngaert, Amy Axel, Tine Casneuf, Hilde Bohets, Angibaud Patrick, Rajendra Kumari, Sue Watson, Janine Arts, McClue Steve, Martin Page

Cancer Res (2011) 71 (8_Supplement): 2606.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2606

Published: 15 April 2011

View article

Journal Articles

Abstract 5443: Rational combinations with the HDAC inhibitor JNJ-26481585: Prostate cancer and taxane therapy

Ian Hickson, Peter King, Ann Marien, Veronique Vreys, Marc Janssen, Tinne Verhulst, Boudewijn Janssens, Patrick Angibaud, Rajendra Kumari, Sue Watson, Martin Page, Janine Arts

Cancer Res (2010) 70 (8_Supplement): 5443.

DOI: https://doi.org/10.1158/1538-7445.AM10-5443

Published: 15 April 2010

View article

Journal Articles

Abstract 5440: Study of the mechanism of action and pharmacodynamic response of JNJ-26481585, a potent histone deacetylase inhibitor in the setting of melanoma

Robert Te Poele, Simon Heaton, Michelle Garrett, Peter Hellemans, Ian Hickson, Janna Sand-Dejmek, Jeffrey TR Evans, Johann S. de Bono, Udai Banerji

Cancer Res (2010) 70 (8_Supplement): 5440.

DOI: https://doi.org/10.1158/1538-7445.AM10-5440

Published: 15 April 2010

View article

Journal Articles

Abstract 5441: Preclinical assessment of the HDAC inhibitor JNJ-26481585: potent in vivo activity across a broad spectrum of human tumor xenografts

Ian Hickson, Peter King, Ann Marien, Lut Janssen, Wim Floren, Tinne Verhulst, Boudewijn Janssens, Patrick Angibaud, Martin Page, Janine Arts

Cancer Res (2010) 70 (8_Supplement): 5441.

DOI: https://doi.org/10.1158/1538-7445.AM10-5441

Published: 15 April 2010

View article

Journal Articles

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Cancer Res (2010) 70 (1): 288–298.

DOI: https://doi.org/10.1158/0008-5472.CAN-09-1751

Published: 04 January 2010

View article

Includes: Supplementary data

Journal Articles

Abstract #3301: Phenotypic kinase inhibitor screening: A systems biology approach to drug discovery.

Karine Smans, Sabine De Breucker, Berthold Wroblowski, Miroslav Cik, Inez Van De Weyer, Ian Hickson, Eddy Freyne, Janine Arts, Martin Page

Cancer Res (2009) 69 (9_Supplement): 3301.

Published: 01 May 2009

View article

Journal Articles

Abstract #4770: Characterization of AZD8055, a potent selective inhibitor of mTORC1 and mTORC2 kinase

Christine Chresta, Barry Davies, Tom Harding, Ian Hickson, Sabina Cosulich, Susan Critchlow, Patrizia Sini, Dominic James, Karine Malagu, Marc Hummersone, Graeme Smith, Martin Pass, Sylvie Guichard

Cancer Res (2009) 69 (9_Supplement): 4770.

Published: 01 May 2009

View article

Journal Articles

Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of rapamycin (mTOR)

Ian Hickson, Lisa Smith, Sharon Maguire, Heather Duggan, Karine Malagu, Marc Hummersone, Keith Menear, Christine Chresta, Barry Davies, Martin Pass, Niall Martin, Graeme Smith

Cancer Res (2008) 68 (9_Supplement): 1422.

Published: 01 May 2008

View article

Journal Articles

Cellular differentiation of rapamycin, PI3 kinase and TOR kinase inhibitors

Christine Chresta, Sam Butterworth, Sabina Cosulich, Nicola Curtis, Sara Davenport, Barry Davies, Rebecca Ellston, Tom Harding, Eric Newboult, Donald Ogilvie, Paul Smith, Martin Pass, Ian Hickson, Karine Malagu, Marc Hummersone, Kurt Pike, Lisa Drew, Lihua Yu, David Brandon

Cancer Res (2008) 68 (9_Supplement): 3564.

Published: 01 May 2008

View article

Journal Articles

Phosphorylation of the Bloom's syndrome protein (BLM) and co-assembly with checkpoint response proteins after Topoisomerase I-induced replication damage by camptothecin

V. Ashutosh Rao, Ian Hickson, Yves Pommier

Cancer Res (2006) 66 (8_Supplement): 124.

Published: 15 April 2006

View article

Journal Articles

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Ian Hickson, Yan Zhao, Caroline J. Richardson, Sharon J. Green, Niall M. B. Martin, Alisdair I. Orr, Philip M. Reaper, Stephen P. Jackson, Nicola J. Curtin, Graeme C. M. Smith

Cancer Res (2004) 64 (24): 9152–9159.

DOI: https://doi.org/10.1158/0008-5472.CAN-04-2727

Published: 16 December 2004

View article

Journal Articles

Identification and in vitro characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

Ian Hickson, Yan Zhao, Xiaoling Cockcroft, Nicola J. Curtin, Sharon J. Green, Marc Hummersone, Niall Martin, Ian Matthews, Keith Menear, Alisdair I. Orr, Caroline J. Richardson, Laurent Rigoreau, Graeme C. Smith

Cancer Res (2004) 64 (7_Supplement): 1236.

Published: 01 April 2004

View article

NARROW

Abstract 2179: Antitumor activity of JNJ-63576253 (TRC253), a small molecule antagonist of F877L mutant and wild-type androgen receptor

Abstract 359: A high-throughput PPI assay to quantify inhibition of androgen receptor variant 7 (AR-V7) binding to canonical AR full-length (AR-FL) binding partners

Abstract 86: Live-cell profiling of inhibitors targeting the N/C interaction within the androgen receptor

Abstract 2023: Complex in vitro and in vivo prostate cancer models for the PREDECT consortium

Abstract 5386: Disrupting p53:Mdm2 and p53:Mdm4 - Comparative cell-based assays for drug screening

Abstract 4770: Dual activity of abiraterone: CYP17 mediated androgen ablation and direct AR inhibition.

Abstract LB-248: Investigation of tumor cell activity of Abiraterone using in vitro model systems of androgen (A)-responsive prostate cancer

Abstract 2606: Rational combinations with the HDAC inhibitor, JNJ-26481585, in prostate cancer

Abstract 5443: Rational combinations with the HDAC inhibitor JNJ-26481585: Prostate cancer and taxane therapy

Abstract 5440: Study of the mechanism of action and pharmacodynamic response of JNJ-26481585, a potent histone deacetylase inhibitor in the setting of melanoma

Abstract 5441: Preclinical assessment of the HDAC inhibitor JNJ-26481585: potent in vivo activity across a broad spectrum of human tumor xenografts

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Abstract #3301: Phenotypic kinase inhibitor screening: A systems biology approach to drug discovery.

Abstract #4770: Characterization of AZD8055, a potent selective inhibitor of mTORC1 and mTORC2 kinase

Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of rapamycin (mTOR)

Cellular differentiation of rapamycin, PI3 kinase and TOR kinase inhibitors

Phosphorylation of the Bloom's syndrome protein (BLM) and co-assembly with checkpoint response proteins after Topoisomerase I-induced replication damage by camptothecin

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Identification and in vitro characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only